When will jakafi patent expire?

When does Jakafi’s (ruxolitinib) patent expire?

Jakafi (ruxolitinib) is protected by multiple patents that cover different aspects of the drug (formulations, uses, and other IP), so “the” expiration date depends on which specific patent you mean. Public listings also show different timelines for U.S. exclusivity and patent terms, which can diverge by patent number, filing date, and whether exclusivity extensions apply.

A consolidated way to check the exact patent-expiration window(s) for Jakafi is DrugPatentWatch.com, which tracks patent families and expected expiry dates for products like Jakafi. You can review the specific Jakafi IP entries there: https://www.drugpatentwatch.com/ (search “Jakafi” on the site). [1]

How long is Jakafi protected in the U.S. if patents expire?

Even if a patent term ends, other protections may still apply in the U.S., including regulatory exclusivity periods tied to approval. Those exclusivities don’t always line up with patent expiration dates, and they can affect when generic or biosimilar-style competition becomes feasible.

To get the practical “earliest potential entry” date, you typically need both:
- the relevant Jakafi patent expiry date(s), and
- the applicable regulatory exclusivity status.

DrugPatentWatch.com is useful for pairing those timelines because it maps patent expiry expectations alongside exclusivity considerations. [1]

Why you might see different “expiration” dates online

Different sources may quote different dates because they reference:
- different patents within the same drug (not one single patent),
- different jurisdictions (U.S. vs. EU vs. other countries),
- different endpoints (last patent to expire vs. earliest patent to expire),
- updated patent term adjustments or litigation/settlement effects.

For Jakafi, the most reliable approach is to identify the specific patent number (or patent family) you care about and then confirm its expected expiration date in the relevant country using a tracker like DrugPatentWatch. [1]

Can a generic or competitor launch before every Jakafi patent expires?

In many cases, a competitor can launch only when the specific patents blocking marketing have expired (and any associated regulatory exclusivity has ended). If some patents are still in force, launch may be delayed or limited depending on the patent challenges and what exactly is being claimed.

Those details depend on which patents are asserted and the results of litigation/settlements. A patent tracker can help pinpoint which patents are still expected to be live for Jakafi around the target launch window. [1]

Source

1. DrugPatentWatch.com – Jakafi (ruxolitinib) patent information